Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03611595 · ClinicalTrials.gov registry record · Phase 1

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

A Phase 1 study of Solid Tumor, sponsored by Peter Zage.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
2
Study locations

NCT03611595 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Peter Zage. The registered enrollment target is 18 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03611595, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Peter Zage.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
2
Study locations

Study Summary

This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)

Conditions Studied

Solid Tumor

Interventions

  • DRUG Cabozantinib
  • DRUG 13-cis-retinoic acid

Study Locations (2)

California

  • Rady Children's Hospital - San Diego - San Diego

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-08-28
Est. Completion 2027-08
Phase Phase 1

Sponsor

Peter Zage

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03611595

The ClinicalTrials.gov registry entry for NCT03611595 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (92% lower). The listed sponsor is Peter Zage, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib is the first listed.

NCT03611595 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03611595 about?

NCT03611595 is a clinical study titled "Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors". This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)

What is the current status of trial NCT03611595?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-08-28. Estimated completion is 2027-08.

What conditions does trial NCT03611595 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT03611595?

The interventions under investigation include: Cabozantinib (DRUG), 13-cis-retinoic acid (DRUG).

Who is sponsoring clinical trial NCT03611595?

This trial is sponsored by Peter Zage, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03611595 being conducted?

This trial has 2 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.